Tinostamustine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tinostamustine
Accession Number
DB15147
Type
Small Molecule
Groups
Investigational
Description

Tinostamustine is under investigation in clinical trial NCT03452930 (Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma).

Structure
Thumb
Synonyms
Not Available
External IDs
EDO-S 101 / EDO-S-101 / EDO-S101
Categories
UNII
29DKI2H2NY
CAS number
1236199-60-2
Weight
Average: 415.36
Monoisotopic: 414.1589316
Chemical Formula
C19H28Cl2N4O2
InChI Key
GISXTRIGVCKQBX-UHFFFAOYSA-N
InChI
InChI=1S/C19H28Cl2N4O2/c1-24-17-9-8-15(25(12-10-20)13-11-21)14-16(17)22-18(24)6-4-2-3-5-7-19(26)23-27/h8-9,14,27H,2-7,10-13H2,1H3,(H,23,26)
IUPAC Name
7-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-1,3-benzodiazol-2-yl}-N-hydroxyheptanamide
SMILES
CN1C(CCCCCCC(=O)NO)=NC2=CC(=CC=C12)N(CCCl)CCCl

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
58171714
ChEMBL
CHEMBL3989941

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentCutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma (CTCL) / Haematological Malignancies / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Peripheral T-Cell Lymphoma (PTCL) / T-Cell Prolymphocytic Leukemia1
1RecruitingTreatmentGlioblastomas / Gliosarcoma / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System / MGMT-unmethylated Glioblastoma / Unmethylated Glioblastoma / Unmethylated MGMT Gene Promoter1
1RecruitingTreatmentMelanoma, Malignant1
1, 2Active Not RecruitingTreatmentEndometrial Cancer / Ovarian Cancer / Small Cell Lung Cancer (SCLC) / Soft Tissue Sarcoma (STS) / Triple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
1, 2TerminatedTreatmentMultiple Myeloma in Relapse / Multiple Myeloma Progression / Multiple Myeloma With Failed Remission1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP4.61ALOGPS
logP3.72ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)8.92ChemAxon
pKa (Strongest Basic)7.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area70.39 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity110.31 m3·mol-1ChemAxon
Polarizability46.02 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:53 / Updated on March 01, 2020 22:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates